AMP-activated protein kinase is essential for survival in chronic hypoxia

Biochemical and Biophysical Research Communications

Volumn 370, Issue 2, 2008, Pages 230-234

  Borger, Darrell R ^a   Gavrilescu, L Cristina ^b   Bucur, Maria C ^b   Ivan, Mircea ^b   DeCaprio, James A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

AMPK; Apoptosis; Cancer; Hypoxia; mTOR; Rapamycin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL HYPOXIA; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL;

AMINOIMIDAZOLE CARBOXAMIDE; CELL HYPOXIA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RIBONUCLEOTIDES; SIROLIMUS;

EID: 42249091173     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.03.056     Document Type: Article

References (28)

1. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
2. Hardie D.G., Hawley S.A., and Scott J.W. AMP-activated protein kinase-development of the energy sensor concept. J. Physiol. 574 (2006) 7-15
3. Marsin A.S., Bouzin C., Bertrand L., and Hue L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem. 277 (2002) 30778-30783
4. Yun H., Lee M., Kim S.S., and Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J. Biol. Chem. 280 (2005) 9963-9972
5. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., Giordano F.J., Mu J., Birnbaum M.J., and Young L.H. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 114 (2004) 495-503
6. Lee M., Hwang J.T., Lee H.J., Jung S.N., Kang I., Chi S.G., Kim S.S., and Ha J. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J. Biol. Chem. 278 (2003) 39653-39661
7. Terai K., Hiramoto Y., Masaki M., Sugiyama S., Kuroda T., Hori M., Kawase I., and Hirota H. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol. Cell. Biol. 25 (2005) 9554-9575
8. Nagata D., Mogi M., and Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem. 278 (2003) 31000-31006
9. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., and Viollet B. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell. Biol. 26 (2006) 5336-5347
10. Corradetti M.N., and Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 25 (2006) 6347-6360
11. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
12. Arsham A.M., Howell J.J., and Simon M.C. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278 (2003) 29655-29660
13. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., and Kaelin Jr. W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18 (2004) 2893-2904
14. Hahn W.C., Dessain S.K., Brooks M.W., King J.E., Elenbaas B., Sabatini D.M., DeCaprio J.A., and Weinberg R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22 (2002) 2111-2123
15. Seagroves T.N., Ryan H.E., Lu H., Wouters B.G., Knapp M., Thibault P., Laderoute K., and Johnson R.S. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol. Cell. Biol. 21 (2001) 3436-3444
16. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
17. Ivan M., and Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11 (2001) 27-34
18. Stein S.C., Woods A., Jones N.A., Davison M.D., and Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345 (2000) 437-443
19. Corton J.M., Gillespie J.G., Hawley S.A., and Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 229 (1995) 558-565
20. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., and Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 280 (2005) 20493-20502
21. Witters L.A., and Kemp B.E. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-activated protein kinase. J. Biol. Chem. 267 (1992) 2864-2867
22. Saha A.K., Schwarsin A.J., Roduit R., Masse F., Kaushik V., Tornheim K., Prentki M., and Ruderman N.B. Activation of malonyl CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator AICAR. J. Biol. Chem. 275 (2000) 24279-24283
23. Xing Y., Musi N., Fujii N., Zou L., Luptak I., Hirshman M.F., Goodyear L.J., and Tian R. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 278 (2003) 28372-28377
24. Brahimi-Horn M.C., and Pouysségur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem. 43 (2007) 165-178
25. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., and Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95 (1998) 1432-1437
26. Hamanaka Y., Mukai M., Shimamura M., Kitagawa T., Nishida T., Isohashi F., Ito T., Nishizawa Y., Tatsuta M., Matsuda H., and Inoue M. Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia. Biochem. Biophys. Res. Commun. 330 (2005) 318-326
27. Kaper F., Dornhoefer N., and Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 66 (2006) 1561-1569
28. Sosman J.A., Puzanov I., and Atkins M.B. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 13 (2007) 764s-769s